GlassScriptPhysician profile
Matthew L Wilner
NPI 1245284785
$3,409.55
in general payments reported to CMS, 2019-2025
27 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $939 · 2021: $203 · 2022: $1,324 · 2023: $117 · 2024: $143 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,017.55 | 2022 | |
| Neotract INC. | $874.49 | 2020 | |
| Pfizer INC. | $214.67 | 2019-2025 | |
| Astellas Pharma US INC | $213.42 | 2019-2022 | |
| Boston Scientific Corporation | $166.20 | 2019 | |
| Dendreon Pharmaceuticals LLC | $139.40 | 2019-2024 | Provenge |
| Innovation Technologies INC | $96.75 | 2022-2024 | Irrisept |
| Janssen Biotech, INC. | $85.00 | 2019 | |
| Olympus America INC. | $83.21 | 2023-2025 | Itind System |
| Tolmar Pharmaceuticals, INC. | $67.41 | 2021-2022 | |
| Abbvie INC. | $59.41 | 2022-2023 | Botox |
| Novartis Pharmaceuticals Corporation | $54.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $38.17 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $37.77 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Medtronic, INC. | $37.26 | 2025 | V-Loc 180 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $29.69 | 2022 | |
| Tempus Ai, INC | $29.29 | 2024 | |
| Coloplast Corp | $29.25 | 2022-2024 | |
| Procept Biorobotics Corporation | $22.60 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.08 | 2020 | |
| Telix Pharmaceuticals | $21.88 | 2023 | Illuccix |
| Cook Medical LLC | $16.00 | 2025 | Resonance |
| Myovant Sciences INC. | $14.56 | 2021 | |
| Verity Pharmaceuticals INC. | $14.20 | 2023 | Trelstar |
| Myriad Genetic Laboratories, INC. | $13.40 | 2021 | |
| Amgen INC. | $11.63 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wilner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.